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In silico characterisation of putative 
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candidates in African malaria 
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O. Ajibola1,2,17, M. F. Diop1,17, A. Ghansah3, L. Amenga‑Etego4, L. Golassa5, T. Apinjoh6, 
M. Randrianarivelojosia7, O. Maiga‑Ascofare8, W. Yavo9, M. Bouyou‑Akotet10, 
K. M. Oyebola11, B. Andagalu12, U. D’Alessandro1, D. Ishengoma13, A. A. Djimde14, 
E. Kamau15,16* & A. Amambua‑Ngwa1*
Genetic diversity of surface exposed and stage specific Plasmodium falciparum immunogenic 
proteins pose a major roadblock to developing an effective malaria vaccine with broad and long‑
lasting immunity. We conducted a prospective genetic analysis of candidate antigens (msp1, ama1, 
rh5, eba175, glurp, celtos, csp, lsa3, Pfsea, trap, conserved chrom3, hyp9, hyp10, phistb, surfin8.2, 
and surfin14.1) for malaria vaccine development on 2375 P. falciparum sequences from 16 African 
countries. We described signatures of balancing selection inferred from positive values of Tajima’s D 
for all antigens across all populations except for glurp. This could be as a result of immune selection on 
these antigens as positive Tajima’s D values mapped to regions with putative immune epitopes. A less 
diverse phistb antigen was characterised with a transmembrane domain, glycophosphatidyl anchors 
between the N and C‑ terminals, and surface epitopes that could be targets of immune recognition. 
This study demonstrates the value of population genetic and immunoinformatic analysis for 
identifying and characterising new putative vaccine candidates towards improving strain transcending 
immunity, and vaccine efficacy across all endemic populations.
Malaria remains a deadly disease with major economic implications, imposing hardship and marginalization 
of poorly resourced communities, especially in sub-Saharan Africa (sSA). An effective malaria vaccine would 
significantly boost malaria control and elimination efforts. However, genetic diversity and the evolutionary 
arms race between the parasite and the host drives antigenic diversity of surface proteins, and other life cycle 
stage-specific proteins targeted as potential vaccine antigens, thereby hampering the development of a widely 
deployable  vaccine1.
Field trials of some of the most advanced candidate malaria vaccines have shown strain  specificity2,3, rais-
ing the possibility of allele-specific immunity as that seen in vaccines against influenza and other  diseases4–7. 
Most of the current leading malaria vaccine candidates in clinical trials were designed and developed based on 
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clonal laboratory strains, mostly Plasmodium falciparum strain NF54 (clone 3D7), without considering para-
site genetic variability in natural  populations8–12. RTS,S/AS01, the most advanced of these malaria vaccines, is 
based on a subunit of 3D7 circumsporozoite surface protein (CSP) antigen. It has shown moderate (< 50%) and 
time-limited protection in African  children13, partly due to the low prevalence (5.2%) of 3D7-type CSP  alleles9. 
Several other recombinant malaria vaccines are currently being evaluated in clinical trials, such as: EBA region 
II-non-glycosylated (EBA-175 RII NG), apical membrane antigen 1 diversity covering (AMA-1 DiCo), merozoite 
surface protein-3 (MSP3) long synthetic peptide (LSP), and serine repeat antigen-5. Other recombinant malaria 
vaccines in clinical trials are described in a recent review by Salamanca et al10. Additionally, the Cell-Traversal 
protein for Ookinetes and Sporozoites (CelTOS), Thrombospondin Related Adhesion Protein (TRAP), and Liver 
Stage Antigen 1 (LSA1), which target liver stage parasites; merozoite surface proteins (MSP2) which target blood 
stage parasites; and transmission blocking stage vaccines targeting Pfs230, Pfs45/48, Pfs25 and Pfs48/4511,14,15 
are also in advanced development.
Nevertheless, given our incomplete understanding of the complexity of immune responses to infection, the 
parasite’s mechanisms of invasion, and the parasite  genome16–19, most of these vaccine candidates would face 
most of the challenges observed during the RTS,S/ASO1 development. To overcome some of these difficulties 
and improve vaccine efficacy by generating cross-protective multi-strain immunity across diverse natural popula-
tions, next generation vaccines must use innovative design approaches that account for genetic variables such as 
differences in antigen allele haplotypes and their frequencies across P. falciparum  populations1,20.
Exploring the allele frequency spectrum and haplotype diversity of vaccine candidates can inform how natural 
selection and demographic events shape them across multiple populations. For example, characterising genetic 
diversity and signatures of selection in the parasite genome or for specific antigens has been useful in identifying 
genes under balancing selection and genic regions that are immunogenic for further  development20–22. With the 
increase of next generation sequencing and openly accessible genome data from multiple endemic populations, 
future multi-allelic vaccines can benefit from genome scans for signatures of balancing selection. This will allow 
assessment of allele and haplotype frequencies across a broad range of endemic populations, particularly in 
sSA where parasite genetic diversity is  high22. Such in silico diversity and prediction approaches should include 
sequence data obtained across multiple temporal and spatial populations. This could be explored to identify new 
candidates, refine components of current candidate vaccine antigens, with optimal components of relevant alleles 
from both pre-erythrocytic and erythrocytic targets prior to functional characterisation and clinical  trials15.
Here, we conducted population genetic and immunoinformatic analysis of selected malaria candidate vaccine 
antigens using single nucleotide polymorphisms (SNP) from field isolates from 16 African countries. We esti-
mated the extent of genetic diversity in these antigens and evaluated the evidence of balancing selection that could 
be shaping their evolution. From this large population dataset, we described a novel putative candidate vaccine 
antigen—phistb—that could be explored for monovalent vaccine development or as part of a multivalent vaccine. 
Together, this is the largest exploration of candidate vaccines’ genetic diversity for natural populations of malaria 
parasites from sSA, providing a framework for designing future functional studies and effective malaria vaccines.
Methods
Ethical considerations. This study utilized data previously published by the Plasmodium Diversity Net-
work Africa (PDNA)23,24 and the open-source, MalariaGEN (https:// www. malar iagen. net/ proje cts/ pf3k). For 
the PDNA data, field studies were approved by the respective local ethical review committees. Venous blood 
(2–5 ml) was collected from study participants aged > 6 months enrolled under approved protocol(s) in each 
country. All participants and/or their legal guardians provided written informed consent before any study pro-
cedures. All procedures performed in studies involving human participants were in accordance with the Dec-
laration of Helsinki. Samples were leukocyte depleted and extracted DNA sequenced by MalariaGEN at the 
Wellcome Sanger Institute.
To utilize PDNA and the open-source data in the current analysis, this study was elaborated as part of a 
malaria genomic surveillance proposal reviewed and approved by the Gambian Government/MRC Joint Ethics 
Committee. The methods employed in this study were in agreement with the MRCG-LSHTM research govern-
ance policy.
Vaccine candidates. A total of 16 Plasmodium falciparum vaccine antigens were identified and analysed; 
among them, 10 (msp1, ama1, rh5, eba175, glurp, celtos, csp, lsa3, Pfsea and trap) were included as potential vac-
cine antigens. The remaining 6 antigens (conserved chrom3, hyp9, hyp10, phist, and surfin8.2, surfin14.1) were 
identified using Rsb (a metric for comparing integrated extended haplotype homozygosity between popula-
tions), the cross population test for signatures of  selection23. Antigens were classified as pre-erythrocytic (celtos, 
csp, lsa3, Pfsea and trap) or erythrocytic (msp1, ama1, rh5, eba175, glurp, chrom3, hyp9, hyp10, phistb, surfin8.2 
and surfin14.1) candidates based on the P. falciparum life cycle stage of expression.
Sequences. The P. falciparum antigen sequences (2375) used in this study were obtained from PDNA study 
sites from; Gambia (n = 247), Mali (n = 137), Cote-d’Ivoire (n = 70), Ghana (n = 423), Nigeria (n = 34), Cameroon 
(n = 239), Gabon (n = 55), Kenya (n = 64), Tanzania (n = 300), Ethiopia (n = 34) and Madagascar (n = 25)23. Addi-
tionally, open-source sequence data from Guinea (n = 143), Senegal (n = 137), Democratic Republic of Congo 
(n = 112), Mauritania (n = 86) and Malawi (n = 269) (Fig. S1) were accessed via the Pf3K project (https:// www. 
malar iagen. net/ proje cts/ pf3k). Details of the methods and curated genotype data can be accessed from https:// 
www. malar iagen. net/ resou rce/ 26 and associated  publications25.
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Data analysis. Nucleotide diversity analysis and neutrality test. Population genetic analyses were carried 
out on each candidate vaccine dataset to investigate the genetic diversity as well as the frequency of known hap-
lotypes being incorporated into vaccine candidates. The range and distribution of genetic diversity within and 
among the natural P. falciparum populations from individual countries were determined. Population genetic 
parameters were determined using PopGenome R  package26. Nucleotide diversity (π) (average number of nucle-
otide differences per site in pairwise comparisons among DNA sequences) and theta (Ɵ) (population mutation 
rate) was measured for each candidate vaccine antigen by country. Nucleotide diversity was calculated both for 
the entire coding sequence of each antigen and in sliding windows to determine regions of increased diversity. 
Haplotype diversity (Hd) which represents the probability that two randomly sampled alleles are different was 
estimated per antigen and population.
Neutrality tests designed to distinguish between neutrally evolving sequences under mutation-drift equilib-
rium- population expansion and contraction, and sequences evolving under non-neutral processes including 
directional or balancing selection, were derived. We determined Tajima’s D, Fu & Li’s F* and D* statistics. Tajima’s 
D uses the frequency of segregating nucleotide sites, while Fu’s F* uses the distribution of alleles or haplotypes. 
Both tests are based on the principle that a rapid population expansion associated with a non-neutral process 
will show a shift in the allele frequency spectrum compared to a neutral Wright-Fisher model consistent with 
population expansion under neutral evolution. For all the candidate vaccine antigens, Tajima’s D was estimated 
by country using  vcftools27 for the entire antigen region or in consecutive sliding windows of 100 bases. Positive 
Tajima’s D values generally suggest balancing selection, or a population contraction is acting to maintain alleles 
at intermediate frequencies; negative values suggest purifying or positive selection, or population expansion that 
results in an excess of rare alleles.
Linkage disequilibrium (LD). To determine correlation between antigen alleles, pair-wise LD between differ-
ent polymorphic sites was computed based on the genotype correlation coefficient  (r2) index between alleles 
at physically separate loci with a minor allele frequency > 1% across all populations using PLINK v1.90b6.428. 
Within each population,  r2 measures for each antigen were calculated between all pairs of single nucleotide poly-
morphisms (SNP) and observed pair-wise LD  (r2) was averaged for each inter-SNP distance. Decay of LD with 
physical distance between SNP loci was fitted in R version 3.6.
Population differentiation among sampling populations. To assess geneflow between populations, we first esti-
mated genetic differentiation (i.e. the difference in the average diversity within populations compared to that 
among populations) expressed as Wright’s fixation index using whole SNP dataset for each vaccine  candidate29. 
The fixation index (FST) was estimated for pairs of populations using the hierFstat  package30. For interpretation, 
FST values < 0.05 was delineated as low differentiation or high gene flow between population pairs, 0.05–0.15 as 
intermediate, and > 0.25 as high differentiation.
Haplotype cluster network analysis. Genetic relationships between antigen haplotypes of P. falciparum from the 
16 African countries were constructed using the median joining algorithm in the R packages Pegas and  Ape31. 
The haplotype network was computed using haplotype pairwise differences as a distance measure, estimated 
from the number of SNP variants between haplotypes.
B‑cell epitope prediction for vaccine candidates. The random forest algorithm trained on epitopes annotated 
from antibody-antigen protein structures was employed in predicting linear B-cell epitopes for 11 candidate vac-
cine antigens with at least 3 SNPs, by employing BepiPred-2.0 at a threshold of 0.532. Sequences of these antigens 
were uploaded on to the server in FASTA format and B-cell epitopes returned as outputs. We further compared 
the B cell epitopes predicted with segments of the antigens’ sequences with elevated positive Tajima’s D values. 
This allowed us to map contiguous regions in the proteins which are likely under immune selection and could be 
included in future designs of multivalent malaria vaccines.
three‑dimensional structure and membrane anchor prediction for Phistb. The amino acid sequence of the candi-
date vaccine antigen was submitted to I-TASSER for in silico prediction analysis using the default  settings33. The 
predicted model with the highest C-score (range: 0–1), used for indicating confidence in the predicted models, 
was selected and epitopes and regions under balancing selection highlighted. Transmembrane helices and glyco-
phosphatidylinositol (GPI) anchors were predicted by uploading phistb sequence into the TMHMM prediction 
servers and GPI-SOM  respectively34.
Statistical analyses. Spearman’s rank nonparametric correlation coefficient was used to measure the cor-
relation between the three neutrality tests applied. Mann–Whitney U non-parametric test was used to assess 
statistically significant differences between groups assuming a non-Gaussian distribution. Statistical analysis was 
performed using GraphPad Prism version 8.0. Additionally, statistical comparison of genetic indices for antigens 
based on region of origin following stratification of populations into two geographical areas: West and Central 
Africa (Cameroon, Congo, Cote d’Ivoire, Gabon, Gambia, Ghana, Guinea, Mali, Mauritania, Nigeria, and Sen-
egal) versus East Africa (Ethiopia, Kenya, Madagascar, Malawi and Tanzania). This stratification was based on 
previous reports by the PDNA describing the clustering of African malaria parasites into  subpopulations23.
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Results
Study population and candidate vaccine antigens. The population dataset used in this study com-
prise 2375 sequences from West, Central, South Central, East and South-Eastern African countries. Three coun-
tries in the population dataset; Nigeria, Ethiopia and Madagascar had fewer parasite sequences (34, 34, and 25 
respectively) compared to other countries in our analysis.
Polymorphism and haplotype diversity. The lowest median number of haplotypes per country was 
3 for pfsea, and msp1, while the highest was 110 for surfin8.2 (Table S1). All candidate vaccine antigens were 
initially subjected to nucleotide diversity and  FST analyses. The average pairwise nucleotide difference per site 
estimated as π and Ɵ for the pre-erythrocytic (celtos, csp, lsa3 and trap) and erythrocytic (msp1, ama1, rh5, 
eba175, glurp, chrom3, hyp9, hyp10, phistb, Pfsea, surfin8.2 and surfin14.1) antigens showed large nucleotide 
diversity when aggregated across all countries. For the pre-erythrocytic antigens, pfsea had consistently lower π 
and Ɵ values of 0.00002890 and 0.00009980 respectively (Table 1). The erythrocytic antigens hyp9 had the low-
est diversity values (π = 2.538 ×  10−4; θ = 8.066 ×  10−4) whilst hyp10 had the highest (π = 0.016099; θ = 0.011532)
(Table 1). In general, pre-erythrocytic antigens were less diverse than erythrocytic antigens. Nevertheless, when 
disaggregated by country, the π for pre-erythrocytic antigens ranged from as high 0.0175342 for csp (Gabon) to 
as low as 0.0000075 for pfsea (Mauritania). For the erythrocytic antigens, the π value was as high as 0.0189404 for 
hyp10 (Gambia) while the lowest values was 0.0000952 for hyp9 (Cote d’Ivoire), (Table S1). Across all countries, 
we observed relatively higher genetic diversity in csp (except for Ethiopia) and hyp10. Nevertheless, pre-eryth-
rocytic antigens lsa3 and pfsea had low (0.058–0.096) nucleotide diversity across all countries. Such low levels 
of diversity were also observed across geographical sites for erythrocytic antigens rh5, hyp9, and glurp (majority 
of sites). Interestingly, we observed a relatively higher nucleotide diversity at rh5 in east African sites (Kenya, 
Malawi and Tanzania) and the island of Madagascar (Table S1).
The haplotype diversity index (Hd) values across all antigens and populations were mostly > 0.4 with the 
exception of pre-erythrocytic antigen pfsea, (Hd ranging from 0.05 to 0.29) and erythrocytic antigen hyp9 
(0.017–0.153) which were low across all populations (Table S1). Candidate vaccine antigens ama1, eba175 and 
glurp from Ethiopia had lower Hd values than in the other African countries. A similar pattern was observed for 
pre-erythrocytic antigens. However, it is important to note that a small number of samples were analysed from 
Ethiopia. To identify any differences within Africa, we compared Hd values from the two subregions, namely West 
and Central Africa versus East Africa, and found significant differences for lsa3 (P = 0.01), hyp10 (P = 0.0005), 
phistb (P = 0.0005) and rh5 (P = 0.0032). In our subsequent analysis, antigens with limited SNP information were 
excluded, which led to removal of five antigens (pfsea, hyp9, hyp10, conserved chrom3 and rh5) from Tajima’s 
D and LD analysis. The remaining 11 antigens were subjected to Tajima’s D, LD and linear B-cell epitope and 
3D-structure prediction.
Genetic differentiation and gene flow. We evaluated genetic differentiation among parasite popula-
tions to obtain an insight into gene flow by calculating Wright’s fixation index (FST) of inter-population variance 
in allele frequencies. Pairwise FST values for the pre-erythrocytic antigens were low suggesting low genetic dif-
ferentiation among the populations or extensive genetic exchange (high gene flow), with the exception of csp in 
Table 1.  Haplotype diversity of P. falciparum candidate vaccine antigens. Pi and theta nucleotide diversity 
indexes and hd, haplotype diversity.
Vaccine candidates Pi(π) Hd Theta (Ɵ)
Pre-erythrocytic
celtos 0.00165175 0.9860 0.00165175
csp 0.01555860 0.9490 0.01219290
lsa3 0.00059395 0.8705 0.00049910
trap 0.00828865 0.9965 0.00537735
pfsea 0.00002890 0.0990 0.00009980
Erythrocytic
ama1 0.00165175 0.9955 0.00447465
chrom3 0.00483740 0.6690 0.00363820
eba175 0.00181675 0.9930 0.00105945
glurp 0.00099680 0.9555 0.00151625
hyp9 0.00025385 0.0580 0.00080655
hyp10 0.01609915 0.7995 0.01153165
msp1 0.00306515 0.9985 0.00300525
phistb 0.00160080 0.8335 0.00122970
rh5 0.00087060 0.5530 0.00095175
surfin8.2 0.00808670 0.9990 0.00413205
surfin14.1 0.00153700 0.9965 0.00091120
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populations with low samples sizes; Nigeria, Ethiopia and Madagascar, which had high values, FST > 0.25 (Fig. 1). 
The highest pairwise FST value between Ethiopia and Nigeria for csp was (FST = 0.44). Pairwise FST values for 
erythrocytic antigens also showed low genetic differentiation, with the exception of rh5 antigen between Mada-
gascar and Gambia (FST = 0.3), which are separated by the widest geographic distance.
Genetic polymorphisms and haplotype frequency. Across all the neutrality tests (Tajima’s D, Fu & 
Li’s D* and F* summary statistics), values were mostly positive for the candidate vaccine antigens, except for 
glurp which had negative Tajima’s D values (Table S2 & Fig. S2), suggesting low frequency polymorphisms rela-
tive to that expected under neutrality. Tajima’s D values ranged from 4.113 for surfin8.2 in Ghana to 0.456 for 
msp1 in Madagascar; Fu&Li F* ranged from 4.551 for surfin8.2 in Ghana to 1.069 for phistb in Kenya; and Fu&Li 
D* ranged from 3.521 for surfin8.2 in Ghana to 1.004 for phistb in Ethiopia (Table S2). The positive neutrality test 


































































































































































Figure 1.  Pairwise  FST indices of candidate vaccine antigens from the 16 African countries, (a) Pre-erythrocytic 
antigens (b) erythrocytic antigens. Fst indices indicate low genetic differentiation for most of the antigens 
 (FST < 0.05). Ethiopia and Madagascar had few samples, 34 and 25 respectively.
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vaccine antigens across malaria endemic populations in sSA (Table 2). Comparison of Tajima’s D values for the 
candidate vaccine antigens analysed by subregions revealed that for most of the antigens there were no statisti-
cally significant differences (P > 0.05) between East versus West and Central Africa. This is further evidence 
of standing variation in these antigens across malaria endemic communities in sSA. As expected, there was 
strong correlation between Tajima’s D and Fu & Li’s F* values for all the antigens across the populations studied 
(r = 0.882). However, correlation was much lower between Tajima’s D and Fu & Li’s D* (r = 0.03), with some 
antigens, notably glurp, celtos and phistb, showing a negative correlation, while Fu & Li’s D* and F* had a weak 
correlation (r = 0.2) for the antigens except for glurp where Tajima’s D was negative but Fu and Li indices were 
positive (Fig. 2). Tajima’s D becomes negative when there is an excess of rare alleles resulting in more pairwise 
diversity than the number of segregating sites.
Haplotype frequency and cluster network. The frequency of haplotypes for all antigens and details 
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haplotypes across our populations, haplotype networks were constructed on selected vaccine candidates already 
under investigation in clinical trials; 2 pre-erythrocytic (celtos and csp) and 3 erythrocytic (ama1, msp1 and 
phistb) antigens. The pre-erythrocytic antigens had a high number of haplotypes with no geographic clusters, 
suggesting lack of structure. Haplotype network of the erythrocytic antigens followed a similar pattern to the 
pre-erythrocytic antigens, except for phistb where geographic clustering of some haplotypes was evident (Fig. 3).
Linkage disequilibrium. Linkage Disequilibrium (LD) declined rapidly with physical separating pairs of 
SNPs for all antigens, falling below an  r2 of 0.05 within 1000 base pairs (Fig. 4). Exceptionally, LD values were 
higher for Ethiopia, with  r2 > 0.1 across most pairs of SNPs not significantly decaying with physical distance for 
most antigens. This observation may be underscored by variance in malaria transmission dynamics, population 
migration, demography and recombination potential within the SNPs in the genes analysed.
Antigenic potential and 3D structure of phistb. Epitope scanning for linear B cell epitopes on the 
antigens revealed several epitopes. Some of the regions with immune epitopes overlap with regions of high 
Tajima’s D, indicative of immune selection. The list of the B cell epitopes for the vaccine candidates and regions 
mapping with high Tajima’s D are provided in Table  S4. We further explored the immunogenicity of phistb, 
which had only 2 predominant haplotypes (Table S3), and evidence of genetic structure between geographical 
parasite populations. The TMHMM server predicted one transmembrane helix between amino acid positions 
54 and 73, and the likelihood of a signal peptide (Fig. S3). Phistb also has a post-translational modification- gly-
cophosphatidyl inositol (GPI) site in its C-terminal region. GPI is used by proteins for anchoring to the plasma 
membrane (Fig. S4). Following 3D structure modelling of Phistb the linear B-cell epitopes predicted overlapped 
with regions with high positive Tajima’s D values (Fig. 5).
Discussion
We carried out a large-scale population genetic analyses of candidate vaccine antigens and hitherto uncharac-
terised potential antigens using SNP data of P. falciparum isolates (n = 2375) from 16 African countries. Most 
advanced malaria vaccine candidates were initially designed without considering genetic diversity, resulting in 
poor protective efficacy as shown by FMP1/AS02A MSP1 or the AMA1 candidates that had limited vaccine allele 
representation in naturally circulating parasites, especially in  Africa11,35,36. Therefore this focused analysis on 
African parasite populations is relevant, given intense but heterogenous transmission, and high parasite genetic 
diversity across sub-populations3,4.
By screening for antigens with signatures of directional selection, we expected to identify those with domi-
nant haplotypes and exposed immune epitopes, that could be included into the panel of candidates currently 
under development. We observed significant diversity amongst characterised vaccine candidates and new puta-
tive antigens across all populations, and this may result in poor efficacy both within clinical trials and in future 
 deployment37. As immunity could be driving balancing selection signatures against specific domains of the 
antigens, our scan for signatures of selection localised these segments, with sequences of known immune epitopes 
that could be targeted for functional evaluation. However, antigens under high immune selection pressures and 
balancing selection are often highly polymorphic with moderate minor allele frequencies, likely to result in 
variance in allele specific immune response between  populations38. This applies also to well-known erythrocytic 
vaccine candidates based on ama1, msp1 and eba175, in which variation and selection has been a major hurdle 
in achieving broad efficacy across malaria endemic  populations35,37,39. Like msp1 and ama1, other erythrocytic 
antigens such as surfin 8.2 and surfin 14.1 showed signatures of both directional and balancing selection, the 
latter, also due to an excess of intermediate frequency variants that may result in vaccine escape. The surfin fam-
ily of proteins are expressed by genes close to the sub-telomeres where other surface variant antigens (pfemp1, 
rifin, stevor) are  encoded5. These are expressed on the surface of infected erythrocytes and are known targets of 
protective immunity and generating heterologous antibodies associated with reduction in febrile illness due to 
malaria  infection6. Surfin8.2 had the highest number of segregating sites and has been shown to be preferentially 
expressed in  gametocytes40,41. Being a PEXEL (Plasmodium export element) negatively exported protein with a 
transmembrane  domain42, it will be exposed to the surface and can therefore be a target for transmission blocking 
vaccine development. Another transmission blocking vaccine, glurp, is in advanced development alone or as a 
multivalent component with other erythrocytic candidates such as msp3 (GMZ2)43. Its lower Tajima’s D value 
and smaller number of haplotypes could provide an advantage for combination with other candidates such as 
surfin8.2 to provide a broad range of erythrocytic protection and transmission blocking activity.
While erythrocytic antigens dominate the panel of malaria vaccine candidates in development, the only suc-
cessful vaccine to date is the CSP-based RTS,S/AS-01. As shown already, the CSP gene is highly diverse, one of the 
factors contributing to reduced efficacy across populations. We assessed diversity at four other pre-erythrocytic 
candidates, celtos, lsa3, pfsea and trap. The least polymorphic one was the schizont egress antigen pfsea, whose 
antibodies have been associated with protection against high parasitemia and severe  disease44,45. It is under 
preclinical exploration in combination with invariant carboxyl of PfGARP and PfMSP1 in a tri-valent vaccine 
formulation. As previously described, lsa3 also has a low number of haplotypes and is expressed on both sporo-
zoites and the erythrocytic  stages46–48. Thus it could also be considered as a blood stage vaccine candidate given 
its antibodies inhibit parasite growth in the  erythrocyte48. Its further development against both erythrocytic and 
pre-erythrocytic stages will have to consider the African haplotypes described here. This also applies to one of 
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the recent prominent candidates, rh5, which, despite a low number of haplotypes, had 12 non-synonymous SNPs 
and high between population differentiation determined by the fixation index FST. Strong differentiation between 
eastern versus western African parasite populations would imply that population specific variation in haplotypes 
need to be considered for rh5 vaccine development. Our findings also support previous studies which demon-
strated that the number of haplotypes were consistently higher in countries with higher malaria transmission 
such as Cameroon, Mali and  Malawi49–51. Therefore, continuous genetic screening for low diversity candidates 
to add to the pool of current antigens that can be combined in a multivalent malaria vaccine remains important.
We demonstrated the power of this genetic analysis by exemplifying one of the low diversity candidate anti-
gens, phistb. PHIST proteins belong to the Plasmodium helical interspersed subtelomeric (PHIST) family made 
up of 65 gene members (PlasmoDB database, www. plasm odb. org) and are unified by possessing a single domain 
termed PHIST that is predicted to be composed solely of alpha  helices52,53. This family of exported proteins are 
conserved across the human Plasmodium species; P. falciparum, P. vivax and P. knowlesi52. As we identified a 
transmembrane domain and GPI anchors, we expect phistb to be surface  anchored54. Previous studies have 
described phistb to localise to the host erythrocyte periphery through a PRESAN domain and an N-terminal 
sequence, and therefore exposed to immune interaction. Unsurprisingly, segments of the antigen had high 
Tajima’s D values, indicating balancing selection probably due to immune selection. These segments mapped to 
predicted B-cell epitopes which could be included in future candidate vaccine designs, preclinical testing and 
for selection of an optimal vaccine cocktail. The low genetic diversity, limited haplotypes in the population and 
linear B-cell epitopes of phistb are desirable features for designing an antimalarial vaccine that is less likely to 
produce allele-specific immune  responses2,50. Recent studies with in vitro expressed phistb protein demonstrated 
Table 2.  Neutrality tests for candidate vaccine antigens.
Vaccine candidates Tajima_D Fu&Li_F* Fu&Li_D*
Pre-erythrocytic
celtos 0.45 1.59 1.9195
csp 0.599 1.4595 1.595
lsa3 0.872 1.419 1.3525
trap 1.658 2.3895 2.3015
Erythrocytic
ama1 2.443 2.841 2.281
eba175 2.09 2.4335 1.9495
glurp − 0.184 1.1895 1.7725
msp1 0.1915 1.8665 2.5675
phistb 0.6515 1.2785 1.2975
surfin8.2 2.9305 3.5335 2.9885
surfin14.1 0.76175 1.72825 1.9345
Figure 2.  Relationship between Tajima’s D, Fu_Li D* and Fu_LiF*. Positive correlation is indicated by light 
green to deep green, while negative correlation is represented by light yellow to red.
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the presence of significant specific anti-phistb antibodies in children, with malaria specific immune  responses55. 
This further supports predictions from genetic analysis and epitope mapping in line with other studies that have 
identified potential immune targets by modelling protein structures and predicting the functional relevance and 
implications of different domains as vaccine  candidates56,57. PHIST proteins are involved in remodelling infected 
red blood  cells54. However, data on host antimalarial immune responses to these proteins, which could be crucial 
for vaccine development, is scarce.
Despite the relevant finding on top candidates like rh5 and new potential candidates like phistb, our study has 
several limitations. Samples were collected mostly in one field site per country, and thus they may not provide 
an accurate representation of the circulating haplotypes across each country. In addition, the number of samples 
available from some countries such as Madagascar, Ethiopia and Nigeria, were small. Moreover, protocols for 
sample collection differed by country, including the time of sampling, which may influence the parasite hap-
lotypes due to seasonality. The analysis was limited to high quality SNPs, which could have missed important 
genetic variations; and there is also the possibility of ascertainment bias in the dataset that have been utilised in 
this study, and more broader sampling for suspected vaccine candidate genes would be useful. However, despite 
these limitations, the analysis was comprehensive since we used a large dataset and provide a framework and basis 
for future studies and considerations. To verify our findings, functional studies and expanded genetic analysis 
incorporating targeted sequencing data are needed to further support our findings.
In conclusion, despite the broad genetic diversity of antigens of African P. falciparum isolates, it may be 
possible to identify the most prevalent antigen haplotypes within the continent for inclusion in a multivalent 
vaccine. Our findings demonstrate population genetic analysis can be used to identify antigens that consider 
African parasite genetic diversity for design of new vaccines.
Figure 3.  Representative haplotype cluster networks of pre-erythrocytic and erythrocytic vaccine candidates. 
Clustering of haplotypes across populations for pre-erythrocytic candidates (a) CELTOS, (b) CSP, and 
erythrocytic vaccine candidates (c) AMA1, (d) MSP1 and (e) PHISTB. Each node represents a haplotype with 
pies colour coded according to the proportion of haplotypes originating from a specific country. The lengths 
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Figure 4.  Linkage disequilibrium, (a) pre-erythrocytic and (b) erythrocytic vaccine candidates.  R2 values 
decrease as distance increases. LD in Ethiopian samples for both (a) and (b) have a unique decay pattern.
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